145 related articles for article (PubMed ID: 2464022)
1. Induction of tumor-specific in vivo protective immunity by immunization with tumor antigen-pulsed antigen-presenting cells.
Shimizu J; Suda T; Yoshioka T; Kosugi A; Fujiwara H; Hamaoka T
J Immunol; 1989 Feb; 142(3):1053-9. PubMed ID: 2464022
[TBL] [Abstract][Full Text] [Related]
2. Induction of tumor-specific in vivo protective immunity by immunization with tumor antigen-pulsed antigen-presenting cells.
Hamaoka T; Shimizu J; Suda T; Fujiwara H
Princess Takamatsu Symp; 1988; 19():265-75. PubMed ID: 3269360
[TBL] [Abstract][Full Text] [Related]
3. Evidence for the functional binding in vivo of tumor rejection antigens to antigen-presenting cells in tumor-bearing hosts.
Shimizu J; Zou JP; Ikegame K; Katagiri T; Fujiwara H; Hamaoka T
J Immunol; 1991 Mar; 146(5):1708-14. PubMed ID: 1993850
[TBL] [Abstract][Full Text] [Related]
4. Tumor-bearing mice exhibit a progressive increase in tumor antigen-presenting cell function and a reciprocal decrease in tumor antigen-responsive CD4+ T cell activity.
Zou JP; Shimizu J; Ikegame K; Yamamoto N; Ono S; Fujiwara H; Hamaoka T
J Immunol; 1992 Jan; 148(2):648-55. PubMed ID: 1345922
[TBL] [Abstract][Full Text] [Related]
5. Tumor antigen presentation by murine epidermal cells.
Grabbe S; Bruvers S; Gallo RL; Knisely TL; Nazareno R; Granstein RD
J Immunol; 1991 May; 146(10):3656-61. PubMed ID: 2026885
[TBL] [Abstract][Full Text] [Related]
6. [Biochemical characterization of tumor rejection antigen (TRA) and genetic control in anti-TRA immune responses].
Fujiwara H; Suda T; Shimizu J; Muramatsu M; Kimura K; Hamaoka T
Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 2):646-52. PubMed ID: 2468311
[TBL] [Abstract][Full Text] [Related]
7. Separation of the tumor rejection antigen of Rous sarcoma virus-induced murine fibrosarcoma.
Suda T; Shimizu J; Mizushima Y; Fujiwara H; Hamaoka T
Jpn J Cancer Res; 1988 Mar; 79(3):365-74. PubMed ID: 2453498
[TBL] [Abstract][Full Text] [Related]
8. Afferent and efferent specificity in the induction and elicitation of parental cross-protective immunity by an immunogenic murine tumor variant: associative recognition of a unique tumor-specific antigen on somatic cell hybrids.
LeGrue SJ; Ananthaswamy HN; Simcik WJ
Cancer Res; 1989 Sep; 49(17):4747-51. PubMed ID: 2474372
[TBL] [Abstract][Full Text] [Related]
9. A role of interferon-gamma (IFN-gamma) in tumor immunity: T cells with the capacity to reject tumor cells are generated but fail to migrate to tumor sites in IFN-gamma-deficient mice.
Nakajima C; Uekusa Y; Iwasaki M; Yamaguchi N; Mukai T; Gao P; Tomura M; Ono S; Tsujimura T; Fujiwara H; Hamaoka T
Cancer Res; 2001 Apr; 61(8):3399-405. PubMed ID: 11309299
[TBL] [Abstract][Full Text] [Related]
10. Differential ability of tumor-unique and cross-reactive antigen(s) on two murine hepatoma cell lines to induce Lyt-1+2- T cells responsible for in vivo protective immunity.
Shima J; Yoshioka T; Kosugi A; Ogata M; Fujiwara H; Hamaoka T; Ueda S; Kato S
Biken J; 1987 Mar; 30(1):1-8. PubMed ID: 2445335
[TBL] [Abstract][Full Text] [Related]
11. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage.
Labeur MS; Roters B; Pers B; Mehling A; Luger TA; Schwarz T; Grabbe S
J Immunol; 1999 Jan; 162(1):168-75. PubMed ID: 9886383
[TBL] [Abstract][Full Text] [Related]
12. Macrophage processing of antigen for induction of tumor immunity.
Brunda MJ; Raffel S
Cancer Res; 1977 Jun; 37(6):1838-44. PubMed ID: 66987
[TBL] [Abstract][Full Text] [Related]
13. Studies on the induction of tolerance to alloantigens. I. The abrogation of potentials for delayed-type-hypersensitivity response to alloantigens by portal venous inoculation with allogeneic cells.
Qian J; Hashimoto T; Fujiwara H; Hamaoka T
J Immunol; 1985 Jun; 134(6):3656-61. PubMed ID: 2580893
[TBL] [Abstract][Full Text] [Related]
14. Influence of tumor antigen on maintenance versus depression of tumor-specific immunity.
Vaage J
Cancer Res; 1973 Mar; 33(3):493-503. PubMed ID: 4689898
[No Abstract] [Full Text] [Related]
15. Macrophages induce cellular immunity by activating Th1 cell responses and suppressing Th2 cell responses.
Desmedt M; Rottiers P; Dooms H; Fiers W; Grooten J
J Immunol; 1998 Jun; 160(11):5300-8. PubMed ID: 9605128
[TBL] [Abstract][Full Text] [Related]
16. Protective immunity to progressive tumors can be induced by antigen presented on regressor tumors.
Flood PM; Schreiber H; Ron Y
J Immunol; 1987 May; 138(10):3573-9. PubMed ID: 3571978
[TBL] [Abstract][Full Text] [Related]
17. Anti-Gal-mediated targeting of human B lymphoma cells to antigen-presenting cells: a potential method for immunotherapy using autologous tumor cells.
Manches O; Plumas J; Lui G; Chaperot L; Molens JP; Sotto JJ; Bensa JC; Galili U
Haematologica; 2005 May; 90(5):625-34. PubMed ID: 15921377
[TBL] [Abstract][Full Text] [Related]
18. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
[TBL] [Abstract][Full Text] [Related]
19. In vivo treatment with monoclonal anti-I-A antibodies: disappearance of splenic antigen-presenting cell function concomitant with modulation of splenic cell surface I-A and I-E antigens.
Kruisbeek AM; Titus JA; Stephany DA; Gause BL; Longo DL
J Immunol; 1985 Jun; 134(6):3605-14. PubMed ID: 2580891
[TBL] [Abstract][Full Text] [Related]
20. Soluble factors produced during an immune response regulate Ia antigen expression by murine adenocarcinoma and fibrosarcoma cells.
Callahan GN
J Immunol; 1984 May; 132(5):2649-57. PubMed ID: 6201554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
